Inside USP: Heparin Monographs Further Revised - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Inside USP: Heparin Monographs Further Revised
USP's Stage 2 heparin monograph revisions address identification, potency, and impurities.

Pharmaceutical Technology
Volume 33, Issue 3, pp. 136-137

Potency. The pharmacopeial heparin potency assay traditionally was performed using sheep plasma. The rationale for this method is that it resembles as closely as possible the actual situation in which heparin typically is used (i.e., in human blood). Unfortunately, the results of the assay in plasma are affected by other proteins that are present in sheep plasma. Heparin can bind to a large variety of plasma proteins such as histidine-rich glycoprotein, platelet factor 4 (PF-4), and heparin cofactor II (HCII). The large enhancement of antifactor IIa activity for OSCS is an HCII-mediated event (4). This phenomenon explains how contaminated heparin batches successfully passed the USP sheep plasma clotting activity assay. Based on the known modes of action of heparin, USPC proposes to replace the current potency assay based on sheep plasma with a chromogenic antifactor IIa assay that uses purified reagents.

Organic impurities. An Impurity test has been added to quantify the percent galactosamine of total hexosamine in heparin. Heparins are salts of sulfated glucosamino-glycans composed of polymers of alternating D-glucosamine (N-sulfated or N-acetylated) and uronic acid (L-iduronic or D-glucuronic acid) joined by glycosidic linkages. This procedure involves the hydrolysis of heparin into the monomers (galactosamine and glucosamine) by hydrochloric acid and analysis by high-performance ion chromatography. The percent (w/w) of galactosamine with respect to the total amount of both galactosamine and glucosamine (hexosamine) is quantified using the relative response of galactosamine to glucosamine from the chromatograph's peak areas. This test provides a measure of dermatan sulfate and other galactosamine-containing impurities in heparin.

A quantitative Lowry method has replaced the old turbidity test for protein impurities. Nucleotidic impurities and residual solvents have been added to control residual DNA and residual-solvent levels in heparin.


The proposed heparin sodium and heparin sodium injection monographs were posted on the USPC website on Feb. 4, 2009. These Stage 2 monographs will be presented in the March–April Pharmacopeial Forum as proposed Interim Revision Announcements. After review of comments and approval by the BBP EC, the new heparin monographs are expected to become official Aug. 1, 2009.

USPC plans to ensure that any revisions to the monographs are suitable and will not disrupt the supply of safe and effective medicines for patients. Comments on the standards should be sent to
by May 15, 2009.

Anita Y. Szajek, PhD,* is senior scientist, Tina S. Morris, PhD, is director of biologics & biotechnology, William F. Koch, PhD, is chief metrology officer, Darrell R. Abernethy, MD, PhD, is chief science officer, and Roger L. Williams, MD, is chief executive officer, all at the US Pharmacopeia, 12601 Twinbrook Parkway, Rockville, MD 20852-1790, tel. 301.816.8325;

*To whom all correspondence should be addressed.


1. FDA, "Information on Heparin (2009),", accessed Jan. 29, 2009.

2. M. Guerrini et al., "Oversulfated Chondroitin Sulfate Is a Contaminant in Heparin Associated with Adverse Clinical Events," Nature Biotechnol. 26 (6), 669–675 (2008).

3. USP 31–NF 26 <1225>, "Validation of Compendial Procedures," 683–687 (2008).

4. T. Maruyama et al., "Conformational Changes and Anticoagulation Activity of Chondroitin Sulfate Following its O-Sulfonation," Carbohydr. Res., 306, 35–43 (1998).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here